Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.59 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 3/20 | 0.47 |
| ▸ | PTGFR | P43088 | 5/20 | 0.45 |
| ▸ | CASP3 | P42574 | 4/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2823276 | 0.90 | RXFP1 (0.73) | PRNPPPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL2821080 | 0.86 | PRNP (0.56) | PRNPPPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL3970605 | 0.86 | PRNP (0.79) | PRNPPPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL3970468 | 0.85 | ALDH1A1 (0.79) | PRNPPPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL2824330 | 0.82 | PRNP (0.61) | PRNPPPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL13881531 | 0.81 | RXFP1 (0.60) | PRNPPPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL13881528 | 0.80 | ALDH1A1 (0.60) | PRNPPPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL3966576 | 0.80 | PRNP (0.56) | PRNPPPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL3964820 | 0.79 | PRNP (0.58) | PRNPPPARGRXFP1NR2E3NCOR2 | |
| SCHEMBL2825632 | 0.78 | ESR1 (0.37) | PRNPPPARGRXFP1NR2E3NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809605-B1 | QUINOLINES AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | claimed |
| CN-101068788-A | As GABABQuinoline compounds as allosteric enhancers of receptors | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | claimed |
| EP-1809605-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. Hoffmann-Roche AG (CH) | 2007-07-25 | — | — | EP | claimed |
| WO-2006048146-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-11 | — | — | WO | claimed |
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-05-04 | — | — | US | claimed |
| EP-1809605-B1 | QUINOLINES AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7576217-B2 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| CN-101068788-A | As GABABQuinoline compounds as allosteric enhancers of receptors | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | disclosed |
| EP-1809605-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. Hoffmann-Roche AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048146-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | GABRB1, GABRB2, GABRA1 | PRNP 3644/4885PPARG 470/4885RXFP1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.